Comparative Pharmacology
Head-to-head clinical analysis: PRISCOLINE versus TRANSDERM NITRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISCOLINE versus TRANSDERM NITRO.
PRISCOLINE vs TRANSDERM-NITRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Priscoline (tolazoline) is a competitive alpha-adrenergic receptor antagonist; also has direct vasodilatory and histamine-like effects, leading to peripheral vasodilation and decreased peripheral vascular resistance.
Nitroglycerin is converted to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
10-50 mg subcutaneously or intramuscularly every 4-6 hours; intravenous administration (10 mg slow IV push) reserved for acute vasospastic episodes.
Initial dose 0.2-0.4 mg/hour transdermally once daily. Titrate to 0.4-0.8 mg/hour. Maximum 0.8 mg/hour.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults; prolonged in renal impairment.
Terminal elimination half-life is approximately 1-4 minutes after IV administration due to rapid metabolism. After transdermal application, the apparent half-life is 3-4 hours due to continued absorption from the skin depot, resulting in a prolonged clinical effect.
Primarily renal excretion of unchanged drug (approximately 90%); minor fecal excretion (<10%).
Renal (primarily) and biliary; ~60-80% of the dose is excreted renally as metabolites, with <1% unchanged. Fecal excretion accounts for ~10-20%.
Category C
Category C
Vasodilator
Vasodilator